Temperature Management Devices Are Hot

Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. This has given rise to a group of medical device companies formed in the mid-to-late 1990s dedicated to developing temperature management systems. The big question has ben whether clinical data would validate the bets these companies made in this space. Early clinical data released recently has been positive, and large companies are interested in this area, sparking the first major temperature management deal.

One person was trapped in the snow; another fell into an icy lake; the tales have been told of people suffering some type of neurological or cardiac event in which damage was minimized because of exposure to extreme cold. Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. Between 1996 and 1998 these hypotheses gave rise to a group of medical device start-ups dedicated to developing temperature management systems, including Medivance Inc. , Cardeon Corp. , Radiant Medical Inc. , and Innercool Therapies Inc. Other companies operating in this space include Alsius Inc. and Seacoast Technologies Corp. (See "Medical Device's Ice Age," IN VIVO, January 2001 Also see "Medical Device's Ice Age" - In Vivo, 1 January, 2001.; "Medivance: Climate Control for the Body," IN VIVO, July 2001 Also see "Medivance: Climate Control for the Body" - In Vivo, 1 July, 2001.;"Innercool Therapies Inc.," START-UP, January 2000 Also see "Innercool Therapies Inc." - Medtech Insight, 1 January, 2000.;"Radiant Medical Inc.," START-UP, May 2000 Also see "Radiant Medical Inc." - Medtech Insight, 1 May, 2000.;"Cardeon Corp.," START-UP, October 2000 Also see "Cardeon Corp." - Medtech Insight, 1 October, 2000..)

The big question in temperature management has been whether clinical data would validate the bets these companies made in this...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

More from R&D

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.